Carl Zeiss Meditec acquires two manufacturers of surgical instruments
Carl Zeiss Meditec announced today the acquisition of two manufacturers of surgical instruments (Kogent Surgical, LLC and Katalyst Surgical, LLC) to further strengthen its positioning as a solution provider.
Jena, Germany | Carl Zeiss Meditec AG
Kogent Surgical and Katalyst Surgical are based in Chesterfield, Missouri (USA) and were founded by entrepreneur Gregg Scheller. Carl Zeiss Meditec AG President and CEO Dr. Markus Weber states: "This is a strategically important acquisition for ZEISS Medical Technology. We expect this acquisition to scale the businesses and contribute to our surgical solution offering and add recurring revenue." Gregg Scheller comments: "We already have a successful, long-term partnership with ZEISS and FCI (France Chirurgie Instrumentation S.A.S.) and we look forward to jointly expanding our solutions into other ZEISS applications and customer specialties." Financial terms of the deal are not disclosed.
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at www.zeiss.com/med